`
`/MB/
`
`Sheet 1 of 1
`
`APPLN. NO.
`DOCKET NO.
`Form PTO-1449
`
`U.S. Department of Commerce 046483-6001US13(01088)|14/997,136
`APPLICANT:
`Carl H. June, et al.
`FILING DATE:
`January
`15, 2016
`
`Supplemental
`Information Disclosure Statement
`
`GROUP:
`1653
`
`U.S. PATENT DOCUMENTS
`
`
`
`Initial
`
`
`
`
`
`
`
`appropriate
`
`Examiner DocumentNumber|ae Name Class Subclass FilingDate if
`
`rrPATENTDOCUMENTS
`—[preasoINO 2005044986|19 May2005 erpEp
`
`eeeeeeeeee
`
`OTHER DOCUMENT(S) (Uncluding Author, Title, Date, Pertinent Pages, etc.)
`Colombian Patent Application No. 15-80428 — Office Action issued December 23, 2015.
`
`2015
`
`= ColombianPatentApplicationNo. -No. 13-137536—OfficeActionissuedNovember23,
`—}]sPaeinS55=rOraadsy518—U.S. PatentApplicationNo. 13/992,622—FinalOfficeActionissuedJanuary5,2016
`
`
`
`
`
`04/18/2016
`
`“Genetically Engineered Lymphocyte Therapyin Treating Patients with B-Cell Leukemia or
`Lymphoma Thatis Resistant or Refractory to Chemotherapy” ClinicalTrials.gov Identifier
`NCT01029366; Retrieved from the internet on January 29, 2016. Found at
`ritos /Avww. clinicaltrials govict2/show/NUT0141 029366Mern=NCTS 1 O293668rank= 1
`“Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and
`Lymphoma (CART-19)” ClinicalTrials.gov Identifier; NCT00891215; Retrieved from the
`internet on September 2, 2015. Found at
`hilo /Aveb. archive orgéveb/20090903002 304inite //ciinicalirials govict2/snow/NCT00
`891215
`
`
`
`
`
`
`
`
`
`
`
`|_| Eurasian Patent|EurasianPatentApplicationNo.201390847—OfficeActionissuedFebruary14,2016|No. 201390847 — Office Action issued February 14, 2016
`
`U.S. Patent Application No. 14/996,953 — non-final Office Action issued February 22, 2016
`
`Pf| AppliChem product sheet for RPMI-1640, 2 pages, downloaded 12/28/2015
`Pf| Milone, M.et al., Supplementary Materials and Methods, Mol Ther, Vol. 17, 2009, 7 pages
`
`Examiner Signature:
`
`Date Considered:
`
`‘Michael Burkhart/
`
`*EXAMINER:Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line throughcitation if not in conformance and not considered.
`Include copy of this form with next communication to applicant(s).
`UPenn Ex. 2027
`Miltenyi v. UPenn
`IPR2022-00855
`Page 1
`
`UPenn Ex. 2027
`Miltenyi v. UPenn
`IPR2022-00855
`Page 1
`
`